Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonist attenuate tumor growth via polarization of neutrophils toward an antitumor phenotype

Sanjeeb Shrestha, Jae Myoung Noh, Shin Yeong Kim, Hwa Yong Ham, Yeon Ja Kim, Young Jin Yun, Min Ju Kim, Min Soo Kwon, Dong Keun Song, Chang Won Hong

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Tumor microenvironments polarize neutrophils to protumoral phenotypes. Here, we demonstrate that the angiotensin converting enzyme inhibitors (ACEis) and angiotensin II type 1 receptor (AGTR1) antagonist attenuate tumor growth via polarization of neutrophils toward an antitumoral phenotype. The ACEis or AGTR1 antagonist enhanced hypersegmentation of human neutrophils and increased neutrophil cytotoxicity against tumor cells. This neutrophil hypersegmentation was dependent on the mTOR pathway. In a murine tumor model, ACEis and AGTR1 antagonist attenuated tumor growth and enhanced neutrophil hypersegmentation. ACEis inhibited tumor-induced polarization of neutrophils to a protumoral phenotype. Neutrophil depletion reduced the antitumor effect of ACEi. Together, these data suggest that the modulation of Ang II pathway attenuates tumor growth via polarization of neutrophils to an antitumoral phenotype.

Original languageEnglish
JournalOncoImmunology
Volume5
Issue number1
DOIs
StatePublished - 2016

Keywords

  • Angiotensin converting enzyme inhibitor
  • Angiotensin II
  • Angiotensin II type 1 receptor antagonist
  • Innate immunity
  • Myeloid-derived suppressor cell
  • Neutrophil
  • Tumor immunology

Fingerprint

Dive into the research topics of 'Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonist attenuate tumor growth via polarization of neutrophils toward an antitumor phenotype'. Together they form a unique fingerprint.

Cite this